Hot BiotecH Stocks: Alnylam Pharmaceuticals (NASDAQ:ALNY), Sangamo Biosciences (NASDAQ:SGMO), Dyax Corp. (NASDAQ:DYAX), Synthetic Biologics Inc (NYSEMKT:SYN)

It was the biggest loser on the Bloomberg Massachusetts Index: Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), down more than 12 percent. The Cambridge company is developing a new class of medicines based on RNA interference, or RNAi. Alnylam believes that RNAi therapeutics are a promising approach to silence disease-causing genes, according to its website. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock performance was -12.11% in last session and finished … Continue reading Hot BiotecH Stocks: Alnylam Pharmaceuticals (NASDAQ:ALNY), Sangamo Biosciences (NASDAQ:SGMO), Dyax Corp. (NASDAQ:DYAX), Synthetic Biologics Inc (NYSEMKT:SYN)

Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

On Apr 3, Zacks Investment Research upgraded ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s loss estimates have declining on the back of better-than-expected fourth quarter 2013 results. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -6.06% in last session and finished the day at $4.34. Traded volume was 1.86million shares in the last session and the average volume of … Continue reading Biotech losers: ZIOPHARM Oncology (NASDAQ:ZIOP), Sangamo Biosciences (NASDAQ:SGMO), Lexicon Pharmaceuticals (NASDAQ:LXRX), XOMA Corp (NASDAQ:XOMA)

The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient’s bone marrow, is Incyte (NASDAQ:INCY) and Novartis’ Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal transduction; therefore, blocking JAK2 can inhibit the development cytokines that … Continue reading Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

HIV usually infects blood cells through a protein on their surface, a “docking station” called CCR5. A California company, Sangamo BioSciences Inc. (NASDAQ:SGMO), makes a treatment that can knock out a gene that makes CCR5. Sangamo Biosciences, Inc. (NASDAQ:SGMO) stock performance was 17.08% in last session and finished the day at $22.96. Traded volume was 11.36 million shares in the last session and the average … Continue reading Hot Biotech Gainers: Sangamo Biosciences (NASDAQ:SGMO), CEL-SCI Corporation (NYSEMKT:CVM), Agios Pharmaceuticals (NASDAQ:AGIO), Lpath (NASDAQ:LPTN)

Nokia Corporation (ADR) (NYSE:NOK) is set to release its second-quarter 2014 results before the opening bell on Jul 24, 2014. In the last quarter, the company delivered a positive 50.00% earnings surprise. Likewise, the company has delivered positive earnings surprises in three of the last four quarters, with an average beat of 77.78%. Let’s see how things are shaping up for this announcement. Nokia Corporation … Continue reading Investors Are Watching – Nokia Corporation (ADR) (NYSE:NOK) , Facebook (NASDAQ:FB) , Sangamo Biosciences (NASDAQ:SGMO) , RPM International (NYSE:RPM) , Bottomline Technologies (NASDAQ:EPAY)

Intrexon Corp (NYSE:XON) COO Krish Krishnan purchased 20,900 shares of Intrexon Corp (NYSE:XON) stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $14.21 per share, for a total transaction of $296,989.00. Following the purchase, the chief operating officer now directly owns 20,900 shares in the company, valued at approximately $296,989. Intrexon Corp (NYSE:XON) stock performance … Continue reading Biotech Volatile Stocks: Intrexon Corp (NYSE:XON), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Sangamo Biosciences, Inc. (NASDAQ:SGMO), Osiris Therapeutics, Inc. (NASDAQ:OSIR)